Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension

BMC Ophthalmology

Volumn 11, Issue 1, 2011, Pages

  Zhao, Jia Liang ^a   Ge, Jian ^b   Li, Xiao Xin ^c   Li, Yu Min ^d   Sheng, Yao Hua ^e   Sun, Nai Xue ^f   Sun, Xing Huai ^g   Yao, Ke ^d   Zhong, Zheng ^h  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d ZHEJIANG UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f XI'AN JIAOTONG UNIVERSITY   (China)

^g EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

^h Pfizer Investment Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS; LATANOPROST; PROSTAGLANDIN F; TIMOLOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; ETHNOLOGY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PATHOPHYSIOLOGY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PREVALENCE; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; TIME FACTORS; TIMOLOL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051789404     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-11-23     Document Type: Article

References (41)

1. World Population Prospects: The 2004 Revision. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, Highlights New York: United Nations 2005 http://www.un.org/esa/population/ publications/WPP2004/2004Highlights-finalrevised.pdf Accessed January 18, 2011
2. The epidemiology of age-related eye diseases in Mainland China. Zhou Q, Friedman DS, Lu H, Duan X, Liang Y, Yang X, Wang F, Wang N, Ophthalmic Epidemiol 2007 14 399 407 10.1080/09286580701331974 18161614
3. Pharmacological therapy for glaucoma: a review. Hoyng PF, van Beek LM, Rugs 2000 59 411 434 (Pubitemid 30213853)
4. New developments in the drug treatment of glaucoma. Hurvitz LM, Kaufman PL, Robin AL, Weinreb RN, Crawford K, Shaw B, Drugs 1991 41 514 532 10.2165/00003495-199141040-00002 1711957 (Pubitemid 21920739)
5. Management of glaucoma: focus on pharmacological therapy. Marquis RE, Whitson JT, Drugs Aging 2005 22 1 21 10.2165/00002512-200522010-00001 16506439
6. Medical interventions for primary open angle glaucoma and ocular hypertension. Vass C, Hirn C, Sycha T, Findl O, Bauer P, Schmetterer L, Cochrane Database Syst Rev 2007 4 D003167 17943780
7. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. Kobelt-Nguyen G, Gerdtham UG, Alm A, J Glaucoma 1998 7 95 104 9559495 (Pubitemid 28196096)
8. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Toris CB, Camras CB, Yablonski ME, Ophthalmology 1993 100 1297 1304 8371915 (Pubitemid 23274021)
9. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Alm A, Stjernschantz J, Scandinavian Latanoprost Study Group, Ophthalmology 1995 102 1743 1752 9098273 (Pubitemid 26004426)
10. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma subjects treated concomitantly with timolol. Alm A, Widengård I, Kjellgren D, Söderström M, Friström B, Heijl A, Stjerschantz J, Br J Ophthalmol 1995 79 12 16 10.1136/bjo.79.1.12 7880782
11. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Camras CB, United States Latanoprost Study Group, Ophthalmology 1996 103 138 147 8628544 (Pubitemid 26046170)
12. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Watson P, Stjernschantz J, Latanoprost Study Group, Ophthalmology 1996 103 126 137 8628543 (Pubitemid 26046169)
13. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Hedman K, Larsson LI, Surv Ophthalmol 2002 47 Suppl 1 77 89 12204703
14. Primary Open-Angle Glaucoma, Preferred Practice Pattern. American Academy of Ophthalmology, San Francisco: American Academy of Ophthalmology 2005 http://www.aao.org/ppp Accessed: January 18, 2011
15. European Glaucoma Society Terminology and Guidelines for Glaucoma, Savona, Italy: DOGMA 3 2008 http://www.eugs.org/eng/EGS-guidelines.asp Accessed August 10, 2011
16. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Bucci MG, the Italian Latanoprost Study Group, J Glaucoma 1999 8 24 30 10084271
17. Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients. Lee PY, Shao H, Camras CB, Podos SM, Ophthalmology 1991 98 1079 1082 1891217
18. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Rulo AH, Greve EL, Hoyng PF, Br J Ophthalmol 1994 78 899 902 10.1136/bjo.78.12.899 7819171
19. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Diestelhorst M, Larsson LI, European-Canadian Latanoprost Fixed Combination Study Group, Ophthalmology 2006 113 70 76 10.1016/j.ophtha.2005.06. 027 16263174 (Pubitemid 43021730)
20. Treatment for glaucoma: adherence by the elderly. Gurwitz JH, Glynn RJ, Monane M, Everitt DE, Gilden D, Smith N, Avorn J, Am J Public Health 1993 83 711 716 10.2105/AJPH.83.5.711 8484454 (Pubitemid 23143002)
21. Compliance in patients prescribed eyedrops for glaucoma. Patel SC, Spaeth GL, Ophthalmic Surg 1995 26 233 236 7651690
22. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS, Am J Ophthalmol 2007 144 533 540 10.1016/j.ajo.2007.06.012 17686450 (Pubitemid 47429615)
23. Glaucoma medication persistence with a fixed combination versus multiple bottles. Higginbotham EJ, Hansen J, Davis EJ, Walt JG, Guckian A, Curr Med Res Opin 2009 25 2543 2547 10.1185/03007990903260129 19731993
24. Use of eyedrops in glaucoma: How can we help to reduce non-compliance? Chawla A, McGalliard JN, Batterbury M, Acta Ophthalmol Scand 2007 85 464 10.1111/j.1600-0420.2007.00882.x 17286557 (Pubitemid 46901501)
25. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Stewart WC, Chorak RP, Hunt HH, Sethuraman G, Am J Ophthalmol 1993 116 176 181 8352302 (Pubitemid 23229078)
26. Do adherence rates and glaucomatous visual field progression correlate? Rossi GCM, Pasinetti GM, Scudeller, Radaelli R, Bianchi PE, Eur J Ophthalmol 2010
27. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Higginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK, Tressler CS, United States Fixed-Combination Study Group, Arch Ophthalmol 2010 128 165 172 10.1001/archophthalmol.2009.384 20142538
28. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Baudouin C, Acta Ophthalmol 2008 92 1275 1282
29. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical beta-blocker therapy: a systematic review and meta-analysis. Webers CA, Beckers HJ, Zeegers MP, Nuijts RM, Hendrikse F, Schouten JS, Ophthalmology 2010 117 2067 2074 10.1016/j.ophtha.2010.03.024 20619459
30. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Konstas AG, Maltezos AC, Gandi S, Hudgins AC, Stewart WC, Am J Ophthalmol 1999 128 15 20 10.1016/S0002-9394(99)00073-2 10482089 (Pubitemid 29315758)
31. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Konstas AG, Nakos E, Tersis I, Lallos NA, Leech JN, Stewart WC, Am J Ophthalmol 2002 133 753 757 10.1016/S0002-9394(02)01460-5 12036665 (Pubitemid 34580621)
32. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC, Arch Ophthalmol 2005 123 898 902 10.1001/archopht. 123.7.898 16009829 (Pubitemid 41057985)
33. A comparison of the fixed combination of latanoprost and timolol with its individual components. Pfeiffer N, European Latanoprost Fixed Combination Study Group, Graefes Arch Clin Exp Ophthalmol 2002 240 893 899 10.1007/s00417-002- 0553-0 12486510 (Pubitemid 36097111)
34. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Konstas AG, Lake S, Economou AI, Kaltsos K, Jenkins JN, Stewart WC, Arch Ophthalmol 2006 124 1553 1557 10.1001/archopht.124.11.1553 17102001 (Pubitemid 44748727)
35. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol maleate combination. Takmaz T, Aik S, Kürkçüo.ggglu P, Gurdal C, Can I, Eur J Ophthalmol 2008 18 60 65 18203086 (Pubitemid 351428550)
36. Can the concentration of timolol or the frequency of its administration be reduced? Letchinger SL, Frohlichstein D, Glieser DK, Higginbotham EJ, Wilensky JT, Viana MA, Zeimer R, Ophthalmology 1993 100 1259 1262 8341511 (Pubitemid 23226827)
37. Effects of aging on corneal biomechanical properties and their impact on 24-hour measurement of intraocular pressure. Kida T, Liu JH, Weinreb RN, Am J Ophthalmol 2008 146 567 572 10.1016/j.ajo.2008.05.026 18614134
38. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Liu JH, Zhang X, Kripke DF, Weinreb RN, Invest Ophthalmol Vis Sci 2003 44 1586 1590 10.1167/iovs.02-0666 12657596 (Pubitemid 36378585)
39. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Diestelhorst M, Larsson LI, European Latanoprost Fixed Combination Study Group, Br J Ophthalmol 2004 88 199 203 10.1136/bjo.2003.018234 14736774 (Pubitemid 38142086)
40. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative Group, Arch Ophthalmol 2002 120 915 922 12096962 (Pubitemid 34755544)
41. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Palmberg P, Kim EE, Kwok KK, Tressler CS, Latanoprost/Timolol Study, Eur J Ophthalmol 2010 20 708 718 20099236